Henry Schein stock stays anchored by 2025 sales and margin trends

Henry Schein stock is framed by its 2025 revenue base and margin trend, with the latest available company figures still central to the investment case.

Henry Schein stock, tied to US42548G1040, is anchored by 2025 company figures that include $12.7 billion in sales, a 2.3% reported decline, and a 2.6% increase in constant currency. The latest company context also includes operating income of $774 million and diluted EPS of $2.94 for 2025, which gives investors a clear baseline for the next update.

2025 revenue base

Henry Schein reported $12.7 billion in 2025 net sales, down 2.3% from the prior year, while constant currency sales rose 2.6%. That gap between reported and constant-currency growth matters because it shows how foreign exchange and portfolio mix affected the topline in the year.

The same 2025 framework included operating income of $774 million and diluted EPS of $2.94, giving the company a profit profile that investors can compare with future quarters. The numbers also show that Henry Schein remained profitable even as reported revenue slipped.

Margin and earnings

For 2025, Henry Schein said gross profit and operating performance were shaped by distribution scale and specialty business mix, with operating income reaching $774 million on $12.7 billion of sales. That implies a modest operating margin profile for a distributor, and it is the kind of figure that tends to drive valuation debate more than headline revenue alone.

The diluted EPS figure of $2.94 for 2025 adds another comparison point for the next reporting cycle. If future quarters show better conversion from sales to earnings, that will matter more than a simple revenue rebound.

Market value lens

Henry Schein shares trade on the NASDAQ, and the company identity is clear enough to track against its 2025 report base. The market lens therefore starts with the business scale: $12.7 billion in annual sales, $774 million in operating income, and $2.94 in diluted EPS.

Those three figures are the most useful current frame for the stock because they combine scale, profitability, and per-share earnings in one view. They also set a concrete benchmark for any later price move or analyst revision.

Dental and medical mix

Henry Schein remains best known for its dental and medical distribution platform, and that mix is the reason the company can generate multi-billion-dollar annual revenue even when reported growth is uneven. In 2025, the scale of the business was still large enough to support $774 million in operating income.

That operational scale is the main product story for the stock. The company does not need a dramatic product launch narrative to stay relevant; the core business itself is already large and measurable.

Share context

Without a fresh market quote in the available material, the cleanest stock read is the annual-report baseline rather than a daily price snapshot. Henry Schein stock therefore remains best framed through the 2025 metrics: $12.7 billion in sales, 2.3% reported decline, 2.6% constant-currency growth, $774 million in operating income, and $2.94 diluted EPS.

For readers tracking the shares, those figures are the numbers that define the current setup. They provide the reference point for any later rerating, margin improvement, or earnings surprise.

Dental platform

Henry Schein's dental platform remains the company’s most recognizable business line, and it is the segment most investors associate with the brand. The 2025 results show that this platform still supported a business with $12.7 billion in annual sales and a meaningful profit base.

Stock frame

Henry Schein stock should be read through its 2025 operating profile until the next dated update becomes available. The last full-year figures in hand are $12.7 billion in sales, $774 million in operating income, and $2.94 in diluted EPS.

Henry Schein stock fact box

• Company: Henry Schein, Inc.
• ISIN: US42548G1040
• Ticker: NASDAQ: HSIC
• Trading venue: NASDAQ
• Sector / Industry: Health Care Distribution / Dental and medical supplies
• Index membership: S&P 500